Chen, Charles D.
McCullough, Austin
Gordon, Brian
Joseph-Mathurin, Nelly
Flores, Shaney
McKay, Nicole S.
Hobbs, Diana A.
Hornbeck, Russ
Fagan, Anne M.
Cruchaga, Carlos
Goate, Alison M.
Perrin, Richard J.
Wang, Guoqiao
Li, Yan
Shi, Xinyu
Xiong, Chengjie
Pontecorvo, Michael J.
Klein, Gregory
Su, Yi
Klunk, William E.
Jack, Clifford
Koeppe, Robert
Snider, B. Joy
Berman, Sarah B.
Roberson, Erik D.
Brosch, Jared
Surti, Ghulam
Jiménez-Velázquez, Ivonne Z.
Galasko, Douglas
Honig, Lawrence S.
Brooks, William S.
Clarnette, Roger
Wallon, David
Dubois, Bruno
Pariente, Jérémie
Pasquier, Florence
Sanchez-Valle, Raquel
Shcherbinin, Sergey
Higgins, Ixavier
Tunali, Ilke
Masters, Colin L.
van Dyck, Christopher H.
Masellis, Mario
Hsiung, Robin
Gauthier, Serge
Salloway, Steve
Clifford, David B.
Mills, Susan
Supnet-Bell, Charlene
McDade, Eric
Bateman, Randall J.
Benzinger, Tammie L. S.
,
Funding for this research was provided by:
NIH (U19AG032438, R01AG052550-01A1, U01AG042791, U01AG042791-S1, R01AG046179, R01AG53267-S1, P30NS098577)
Article History
Received: 8 December 2022
Accepted: 18 March 2023
First Online: 5 April 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki (version 7) and the International Conference on Harmonization and Good Clinical Practice guidelines. Protocols for the study have received prior approval by the local Institutional Review Board (IRB) or Ethics Committee of each DIAN site and by the Washington University IRB for the Knight ADRC. The clinical trial registration number is NCT01760005.
: Participants or their caregivers provided written informed consent.
: This manuscript does not contain the details, images, or video of any individual person.
: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. Dr. Klunk is a co-inventor of <sup>11</sup>C-PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Dr. Roberson has been on a DSMB for Lilly and a SAB for AGTC and has received licensing fees from Genentech and owns intellectual property related to tau. Dr. Holtzman, currently Professor of Neurology, scientific director of the Hope Center for Neurological Disorders, and Associate Director of the Knight ADRC where the research is being conducted, is an inventor on patients for solanezumab, currently being tested in the DIAN-TU clinical trials. If solanezumab is approved as a treatment for Alzheimer’s disease or Dominantly Inherited Alzheimer’s Disease, Washington University and Dr. Holtzman will receive part of the net sales of solanezumab from Eli Lilly, which has licensed patents related to solanezumab from Washington University.